...
首页> 外文期刊>Clinical and vaccine immunology: CVI >A Single Dose of a DNA Vaccine Encoding Apa Coencapsulated with 6,6′-Trehalose Dimycolate in Microspheres Confers Long-Term Protection against Tuberculosis in Mycobacterium bovis BCG-Primed Mice
【24h】

A Single Dose of a DNA Vaccine Encoding Apa Coencapsulated with 6,6′-Trehalose Dimycolate in Microspheres Confers Long-Term Protection against Tuberculosis in Mycobacterium bovis BCG-Primed Mice

机译:在微球体中单剂量编码与6,6'-海藻糖二霉酸酯共包裹的Apa的DNA疫苗可长期预防牛分枝杆菌BCG为主的小鼠的结核病

获取原文
           

摘要

Mycobacterium bovis BCG prime DNA (Mycobacterium tuberculosis genes)-booster vaccinations have been shown to induce greater protection against tuberculosis (TB) than BCG alone. This heterologous prime-boost strategy is perhaps the most realistic vaccination for the future of TB infection control, especially in countries where TB is endemic. Moreover, a prime-boost regimen using biodegradable microspheres seems to be a promising immunization to stimulate a long-lasting immune response. The alanine proline antigen (Apa) is a highly immunogenic glycoprotein secreted by M. tuberculosis. This study investigated the immune protection of Apa DNA vaccine against intratracheal M. tuberculosis challenge in mice on the basis of a heterologous prime-boost regimen. BALB/c mice were subcutaneously primed with BCG and intramuscularly boosted with a single dose of plasmid carrying apa and 6,6′-trehalose dimycolate (TDM) adjuvant, coencapsulated in microspheres (BCG-APA), and were evaluated 30 and 70 days after challenge. This prime-boost strategy (BCG-APA) resulted in a significant reduction in the bacterial load in the lungs, thus leading to better preservation of the lung parenchyma, 70 days postinfection compared to BCG vaccinated mice. The profound effect of this heterologous prime-boost regimen in the experimental model supports its development as a feasible strategy for prevention of TB.
机译:牛分枝杆菌BCG初免DNA(结核分枝杆菌基因)疫苗接种已显示出比单独的BCG更好的抗结核病(TB)保护作用。对于未来的结核病感染控制,尤其是在结核病流行的国家,这种异源的初免-加强免疫策略可能是最现实的疫苗。此外,使用可生物降解的微球的初免-加强疗法似乎是一种有希望的免疫方法,可以刺激持久的免疫反应。丙氨酸脯氨酸抗原(Apa)是结核分枝杆菌分泌的一种高度免疫原性糖蛋白。这项研究基于异源初免-加强疗法,研究了Apa DNA疫苗对小鼠气管内结核分枝杆菌攻击的免疫保护作用。将BALB / c小鼠皮下注射BCG,并用单剂量携带 apa 和6,6'-海藻糖二甲酸酯(TDM)佐剂的质粒肌内增强,并共封装在微球(BCG-APA)中,并攻击后30天和70天进行评估。与接种BCG的小鼠相比,这种初免-加强策略(BCG-APA)导致肺中细菌负荷的显着减少,从而导致肺实质的更好保存,即感染后70天。这种异源初免-加强疗法在实验模型中的深远影响支持其发展为预防结核病的可行策略。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号